Healthcare entrepreneurship spans everything from hospital chains to gene-editing startups, and the people behind these ventures have reshaped how medicine is practiced, delivered, and paid for. The digital health market alone was valued at $427 billion in 2025 and is projected to reach $2.35 trillion by 2034, which gives a sense of how much opportunity exists. Here are some of the most influential examples across different areas of healthcare.
Thomas Frist Sr. and the For-Profit Hospital Model
Before the late 1960s, most American hospitals were run by nonprofits, religious organizations, or local governments. Dr. Thomas Frist Sr. changed that. In 1961, he opened Park View Hospital in Nashville, Tennessee. Then in 1968, he teamed up with his son, Dr. Thomas Frist Jr., and businessman Jack C. Massey to found Hospital Corporation of America, now known as HCA Healthcare. The idea was simple but radical: run hospitals like a business, with standardized operations and professional management, while still delivering quality care.
Park View Hospital became the first facility acquired by the new company. HCA introduced a model for hospital care that could scale across the country, and it grew into one of the largest healthcare systems in the United States. The for-profit hospital concept they pioneered is now a major segment of the American healthcare landscape.
Robert Langer and Biotech Drug Delivery
Robert Langer, an MIT professor and chemical engineer, is one of the most prolific inventors in medical history. He holds more than 1,000 patents, which have been licensed or sublicensed to more than 300 companies. He has co-founded at least two dozen biotech companies focused on areas ranging from cancer drug delivery to products for hair and skin.
One of his early breakthroughs was developing microparticles that release a substance blocking blood vessel growth, essentially starving tumors by cutting off their blood supply. That work led to a company that eventually merged with Alkermes, a major pharmaceutical firm. What makes Langer unusual is the sheer volume of his output. Most scientist-entrepreneurs build one or two companies over a career. Langer has turned his lab into something closer to a startup factory, translating basic science into commercial products across dozens of medical fields.
Jennifer Doudna and CRISPR Gene Editing
Jennifer Doudna won the Nobel Prize in Chemistry in 2020 for co-developing CRISPR, a tool that lets scientists edit DNA with extraordinary precision. But she’s also a prolific healthcare entrepreneur. She co-founded five companies to bring CRISPR from the lab into clinical use: Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Mammoth Biosciences, and Scribe Therapeutics. Each targets a different application, from direct therapeutics to diagnostics.
One of her early clinical priorities was expanding access to treatments for sickle cell disease, a genetic blood disorder that disproportionately affects people in underserved communities. During the COVID-19 pandemic, Doudna and colleagues at the Innovative Genomics Institute launched an automated coronavirus testing laboratory and began developing a rapid CRISPR-based diagnostic test that could be used outside of traditional lab settings. Her work illustrates how a single scientific breakthrough can branch into multiple companies solving different problems.
Teladoc and the Rise of Telemedicine
Teladoc Health, founded in 2002, is the company most responsible for making virtual doctor visits mainstream. It launched nationally in 2005 and had around 1 million members by the end of 2007, with large employers like AT&T offering it as a health benefit. The company grew through aggressive acquisition, buying competitors Consult A Doctor and AmeriDoc in 2013 and 2014 to become the largest telemedicine provider in the country.
Teladoc went public in July 2015 as the only telemedicine company on the New York Stock Exchange. That same year, it acquired BetterHelp, a behavioral health platform, for $3.5 million. It then expanded into dermatology, sexual health, and chronic care management. By November 2016, Teladoc had 15 million members and roughly 75% market share in US telemedicine. Its biggest deal came in October 2020, when it acquired chronic care company Livongo Health for $13.9 billion.
By 2023, Teladoc was serving 80 million people across its virtual care products with 56 million paid members in the United States. The company also expanded internationally, operating in 130 countries by 2019. In 2021, it introduced Primary360, a full virtual primary care service. Teladoc’s trajectory shows how one company can redefine an entire category of healthcare delivery.
Stéphane Bancel and mRNA Vaccines
Stéphane Bancel became CEO of Moderna in 2011, years before most people had heard of mRNA technology. The core idea was to use messenger RNA to instruct cells to produce proteins that trigger an immune response, replacing the traditional approach of using weakened or inactivated viruses. For nearly a decade, Moderna operated mostly in research mode with no approved products.
That changed dramatically in 2020, when Moderna’s COVID-19 vaccine became one of the first two mRNA vaccines authorized for emergency use. The technology proved it could move from concept to approved product faster than any vaccine platform in history. Moderna has since expanded its pipeline, with European regulators recommending approval of a combined mRNA vaccine targeting both flu and COVID. The company’s success validated mRNA as a platform technology with applications well beyond a single pandemic.
Anne Wojcicki and Consumer Genetics
Anne Wojcicki co-founded 23andMe in 2006 with a straightforward pitch: let ordinary people access their own genetic data through a mail-in saliva test. The company made genetic testing affordable and consumer-friendly at a time when sequencing was still expensive and largely confined to hospitals and research labs. Customers could learn about their ancestry, carrier status for inherited conditions, and genetic health risks.
The path wasn’t smooth. The FDA ordered 23andMe to stop marketing its health-related reports in 2013 over concerns about the accuracy and implications of providing medical genetic information directly to consumers without a doctor’s involvement. The company spent years working with the agency to earn clearances for specific health risk reports. That regulatory battle became a case study in the tension healthcare entrepreneurs face between innovation and oversight. Despite the setbacks, 23andMe brought consumer genetics into the mainstream and built a genetic database of millions of customers that has become valuable for pharmaceutical research.
AI-Driven Drug Discovery
Alice Zhang co-founded Verge Genomics with the goal of building the first pharmaceutical company that fully automated its drug discovery process. The company uses artificial intelligence to predict which drugs are likely to work against diseases like Alzheimer’s, ALS, and Parkinson’s, conditions where no cure currently exists. Instead of screening millions of compounds one by one in the lab, Verge’s algorithms computationally predict promising candidates before any physical testing begins.
The approach aims to avoid the blind alleys that make traditional drug development so slow and expensive. By analyzing molecular-level data to understand what the body actually needs to heal, AI can help scientists design drugs more rationally. This model represents a growing wave of healthcare startups where the core innovation isn’t a single product but a platform that can generate many products faster and cheaper than conventional methods.
A New Generation of Healthcare Founders
Healthcare entrepreneurship isn’t limited to billion-dollar companies. Forbes’ 2024 “30 Under 30” in healthcare highlighted several younger founders tackling specific, underserved problems. Moseley Andrews, Rory Beyer, and Sameer Jafri co-founded Avive Solutions, which focuses on cardiac emergency response technology. David Eng and Nishith Khandwala built Bunkerhill Health to improve medical imaging analysis. Ritika Poddar and Giordana Pulpo co-founded Abstractive Health to streamline clinical data processing.
These companies tend to be narrowly focused, solving one defined problem rather than trying to reinvent an entire sector. That’s partly a reflection of how healthcare regulation works. Getting a medical product to market through the FDA requires navigating pathways that vary enormously depending on the product’s risk level. Lower-risk devices can reach patients relatively quickly, while higher-risk products face the most stringent review process the FDA offers, with significant costs and longer timelines. Startups with limited funding often choose problems where the regulatory path is more manageable, then expand from there.
What connects all of these entrepreneurs, from hospital chain founders in the 1960s to AI-powered drug discovery startups today, is a willingness to challenge how healthcare has traditionally operated. The specific technologies change, but the pattern is consistent: identify a gap where patients are underserved, build a scalable solution, and navigate the unique regulatory and ethical landscape that makes healthcare harder (and slower) than almost any other industry.